Status:
RECRUITING
Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands
Lead Sponsor:
Amsterdam UMC, location VUmc
Collaborating Sponsors:
St. Antonius Hospital
Conditions:
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
18-65 years
Brief Summary
The goal of this observational study is to study the long-term effects of autologous hematopoietic stem cell transplantation (aHSCT) in people with highly active relapsing-remitting multiple sclerosis...
Eligibility Criteria
Inclusion
- All patients approved for treatment with aHSCT in the Netherlands in accordance with the Dutch criteria for aHSCT treatment for RRMS
Exclusion
- Contra-indications for treatment with aHSCT such as known hypersensitivity to the medication used for aHSCT
- Clinically relevant comorbidities preventing safe use of medication used for aHSCT
- Severe clinical depression
- Active addiction to drugs or alcohol
- Active infections such as but not limited to tuberculosis, cytomegalovirus, Epstein-Barr virus, herpes simplex, varicella zoster, viral hepatitis, toxoplasmosis, HIV or syphilis.
- Active malignancy or history of malignancy with the exception of local basal cell carcinoma or carcinoma in situ of the cervix
Key Trial Info
Start Date :
August 25 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2028
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06567197
Start Date
August 25 2023
End Date
September 1 2028
Last Update
August 22 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Amsterdam UMC
Amsterdam, Netherlands
2
St. Antonius Hospital
Nieuwegein, Netherlands